Clozapine discontinuation withdrawal symptoms in schizophrenia

1. Wimberley, T, MacCabe, JH, Laursen, TM, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 2017; 174: 990–998.
Google Scholar | Crossref | Medline2. Cho, J, Hayes, RD, Jewell, A, et al. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand 2019; 139: 237–247.
Google Scholar | Medline3. Siskind, D, Reddel, T, MacCabe, JH, et al. The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study. Psychopharmacology 2019; 236: 1931–1935.
Google Scholar | Crossref | Medline4. Kane, J, Honigfeld, G, Singer, J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.
Google Scholar | Crossref | Medline5. Hippius, H. A historical perspective of clozapine. J Clin Psychiatry 1999; 60 Suppl 12: 22–23.
Google Scholar6. Masuda, T, Misawa, F, Takase, M, et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry 2019; 76: 1052–1062.
Google Scholar | Crossref | Medline7. Takeuchi, H, Borlido, C, Sanches, M, et al. Adherence to clozapine vs. other antipsychotics in schizophrenia. Acta Psychiatr Scand 2020; 142: 87–95.
Google Scholar | Crossref | Medline8. Meyer, J, Stahl, S. The clozapine handbook: Stahl’s handbooks. Cambridge, UK: Cambridge University Press; 2019.
Google Scholar9. Atkinson, JM, Douglas-Hall, P, Fischetti, C, et al. Outcome following clozapine discontinuation: a retrospective analysis. J Clin Psychiatry 2007; 68: 1027–1030.
Google Scholar | Crossref | Medline | ISI10. Shaker, A, Jones, R. Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service. Ther Adv Psychopharmacol 2018; 8: 3–11.
Google Scholar | SAGE Journals | ISI11. Brandt, L, Bschor, T, Henssler, J, et al. Antipsychotic withdrawal symptoms: a systematic review and meta-analysis. Front Psychiatry 2020; 11: 569912.
Google Scholar | Crossref | Medline12. Moncrieff, J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica 2006; 114: 3–13.
Google Scholar | Crossref | Medline | ISI13. Chouinard, G, Samaha, AN, Chouinard, VA, et al. Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom 2017; 86: 189–219.
Google Scholar | Crossref | Medline | ISI14. Borison, RL, Diamond, BI, Sinha, D, et al. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 1988; 24: 260–263.
Google Scholar | Medline15. Meltzer, HY, Lee, MA, Ranjan, R, et al. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology 1996; 124: 176–187.
Google Scholar | Crossref | Medline | ISI16. Diamond, BI, Borison, RL. Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. Psychopharmacol Bull 1986; 22: 900–905.
Google Scholar | Medline17. Viguera, AC, Baldessarini, RJ, Hegarty, JD, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54: 49–55.
Google Scholar | Crossref | Medline18. Cosci, F, Chouinard, G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 2020; 89: 283–306.
Google Scholar | Crossref | Medline19. Kimura, H, Kanahara, N, Sasaki, T, et al. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: results of a 2-year prospective study, including an additional 1-year follow-up. J Psychopharmacol 2016; 30: 795–802.
Google Scholar | SAGE Journals | ISI20. Seppälä, N, Kovio, C, Leinonen, E. Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs 2005; 19: 1049–1055.
Google Scholar | Crossref | Medline | ISI21. Suzuki, T, Kanahara, N, Yamanaka, H, et al. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res 2015; 227: 278–282.
Google Scholar | Crossref | Medline | ISI22. Miodownik, C, Lerner, V, Kibari, A, et al. The effect of sudden clozapine discontinuation on management of schizophrenic patients: a retrospective controlled study. J Clin Psychiatry 2006; 67: 1204–1208.
Google Scholar | Crossref | Medline | ISI23. Ekblom, B, Eriksson, K, Lindström, L.H. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacol 1984; 83: 293–294.
Google Scholar | Crossref | Medline | ISI24. Bastiampillai, T, Forooziya, F, Dhillon, R. Clozapine-withdrawal catatonia. Aust N Z J Psychiatry 2009; 43: 283–284.
Google Scholar | Medline | ISI25. Wang, BZ, Gupta, A, Bastiampillai, T, et al. Recurrent clozapine and lorazepam withdrawal psychosis with catatonia. Aust N Z J Psychiatry 2012; 46: 795–796.
Google Scholar | SAGE Journals | ISI26. Chouinard, G, Chouinard, V-A. New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63–71.
Google Scholar | Crossref | Medline27. Chouinard, G, Chouinard, VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 2008; 77: 69–77.
Google Scholar | Crossref | Medline | ISI28. Dossenbach, MRK, Beuzen, JN, Avnon, M, et al. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin Ther 2000; 22: 1021–1034.
Google Scholar | Crossref | Medline29. Mizuno, Y, McCutcheon, RA, Brugger, SP, et al. Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology 2020; 45: 622–6231.
Google Scholar | Crossref | Medline30. Lin, C-C, Chiu, H-J, Chen, J-Y, et al. Switching from clozapine to zotepine in patients with schizophrenia. J Clin Psychopharmacol 2013; 33: 211–214.
Google Scholar | Crossref | Medline31. Tollefson, GD, Dellva, MA, Mattler, CA, et al. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. J Clin Psychopharmacol 1999; 19: 435–443.
Google Scholar | Crossref | Medline | ISI32. Lu, ML, Pan, JJ, Teng, HW, et al. Metoclopramide-induced supersensitivity psychosis. 2002; 36: 1387–1390.
Google Scholar33. Kent, TA, Wilber, RD. Reserpine withdrawal psychosis: the possible role of denervation supersensitivity of receptors. J Nerv Ment Dis 1982; 170 :502–504.
Google Scholar | Crossref | Medline | ISI34. Durst, R, Teitelbaum, A, Katz, G, et al. Withdrawal from clozapine: the “rebound phenomenon”. Isr J Psychiatry Relat Sci 1999; 36: 122–128.
Google Scholar | Medline | ISI35. Stanilla, JK, de Leon, J, Simpson, GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry 1997; 58: 252–255.
Google Scholar | Crossref | Medline | ISI36. Luchins, DJ, Freed, WJ, Wyatt, RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1980; 137: 1395–1398.
Google Scholar | Crossref | Medline | ISI37. Galova, A, Berney, P, Desmeules, J, et al. A case report of cholinergic rebound syndrome following abrupt low-dose clozapine discontinuation in a patient with type I bipolar affective disorder. BMC Psychiatry 2019; 19: 73.
Google Scholar | Crossref | Medline38. de Leon, J, Stanilla, JK, White, AO, et al. Anticholinergics to treat clozapine withdrawal. J Clin Psychiatry 1994; 55: 119–120.
Google Scholar | Medline39. Yeh, AW, Lee, JW, Cheng, TC, et al. Clozapine withdrawal catatonia associated with cholinergic and serotonergic rebound hyperactivity: a case report. Clin Neuropharmacol 2004; 27: 216–218.
Google Scholar | Crossref | Medline | ISI40. Shiovitz, TM, Welke, TL, Tigel, PD, et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996; 22: 591–565.
Google Scholar | Crossref | Medline41. Simpson, GM, Lee, JH, Shrivastava, RK. Clozapine in tardive dyskinesia. Psychopharmacology 1978; 56: 75–80.
Google Scholar | Crossref | Medline | ISI42. Dilsaver, SC, Kronfol, Z, Sackellares, JC, et al. Antidepressant withdrawal syndromes: evidence supporting the cholinergic overdrive hypothesis. J Clin Psychopharmacol 1983; 3: 157–164.
Google Scholar | Crossref | Medline | ISI43. Ahmed, S, Chengappa, KN, Naidu, VR, et al. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 1998; 59: 472–477.
Google Scholar | Crossref | Medline | ISI44. Vasile, D, Vasiliu, O, Gheorghe, M, et al. Psychotropic drugs discontinuation syndromes in clinical practice. BMMR 2006; 9: 38–41.
Google Scholar45. Wang, W, Wen, H, Sheng, J. Malignant syndrome or withdrawal reaction? Shanghai Arch Psychiatry 2016; 28: 227–229.
Google Scholar | Medline46. Xu, L, Krishnaswamy, S. Switch-associated adverse events: focus on olanzapine. Australas Psychiatry 2018; 26: 635–639.
Google Scholar | SAGE Journals | ISI47. Nayudu, SK, Scheftner, WA. Case report of withdrawal syndrome after olanzapine discontinuation. J Clin Psychopharmacol 2000; 20: 489–490.
Google Scholar | Crossref | Medline | ISI48. Ganguli, R, Brar, JS, Mahmoud, R, et al. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med 2008; 6: 17.
Google Scholar | Crossref | Medline49. Greenberg, LM, Roth, S. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. Am J Psychiatry 1966; 123: 221–226.
Google Scholar | Crossref | Medline50. Melnyk, W, Worthington, A, Laverty, S. Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic in-patients. Can J Psychiatry 1966; 123: 221–226.

留言 (0)

沒有登入
gif